Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: The Company develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol, CryoStor, BloodStor) for cells, tissues, and organs. Products are marketed to cell therapy companies, pharmaceutical firms, and cord blood banks.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 |
|---|---|---|
| Total Revenue | $467,771 | $980,680 |
| Gross Profit | $193,618 | $432,339 |
| Gross Margin | 41% | 44% |
| Operating Loss | $(391,527) | $(785,342) |
| Net Loss | $(537,144) | $(1,068,921) |
| Cash and Cash Equivalents | $67,881 (as of June 30, 2010) | N/A |
| Net Cash Used in Operating Activities | N/A | $(657,540) |
| Total Debt (Related Parties) | $8,488,127 (Principal) | $8,488,127 (Principal) |
| Accrued Interest (Related Parties) | $1,049,038 | $1,049,038 |
| Accumulated Deficit | $(51,280,141) | $(51,280,141) |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 70% ($191,243) for the three months and 52% ($331,207) for the six months compared to the same periods in 2009, driven by higher sales of BloodStor cord blood stem cell freeze media.
- Margin Expansion: Gross margin improved significantly to 41% (Q2) and 44% (YTD) from 21% and 31% respectively in 2009, attributed to the transition from contract manufacturing to internal manufacturing.
- Expense Reduction: Operating expenses decreased substantially. R&D expenses dropped 43% (Q2) and 46% (YTD), while Sales and Marketing expenses fell 45% (Q2) and 28% (YTD) due to workforce reductions and lower trade show costs.
- Debt Restructuring: Long-term related party debt was reclassified as current liabilities. The total principal balance owed to related parties increased to $8,488,127 following additional draws in February and April 2010.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the Company's ability to continue as a going concern due to an accumulated deficit of approximately $51 million and reliance on debt financing.
- Liquidity: Management believes access to amended loan facilities and cash from operations will fund operations through December 31, 2010. However, immediate additional capital is required if access to these facilities is restricted.
- Financing Risks: The Company relies on a Secured Convertible Multi-Draw Term Loan Facility from related parties (Thomas Girschweiler and Walter Villiger). There is no assurance these investors will continue to provide funds or that new capital will be available on non-dilutive terms.
- Subsequent Event: In August 2010, the Company received an additional $250,000 from the related party investors.
- Share-Based Compensation: The Company issued 5,324,815 stock options to directors and employees during the six-month period, resulting in $79,221 of compensation expense.
Investor Verification Checklist
- Debt Maturity: Verify the repayment terms and extension status of the $8.5 million related party debt, which is currently due January 11, 2011.
- Cash Runway: Confirm the Company's ability to generate positive cash flow before the December 31, 2010 liquidity horizon.
- Related Party Dependence: Assess the risk of the Company's operations halting if the two primary investors cease funding.
- Dilution Potential: Review the terms of the 14.6 million outstanding stock options and 2.2 million warrants, which are currently anti-dilutive but could impact equity value in future financings.
- Inventory Levels: Monitor the increase in inventory ($532,431 vs $358,219 in prior year) to ensure it aligns with sales velocity and does not indicate obsolescence.